Interim FDG-PET does not predict outcome in advanced-stage Hodgkin lymphoma patients treated with BEACOPP

被引：3
|
作者：
Adams, Hugo J. A. [1 ]
Kwee, Thomas C. [2 ]
机构：
[1] Univ Amsterdam, Acad Med Ctr, Dept Radiol & Nucl Med, Amsterdam, Netherlands
[2] Univ Groningen, Univ Med Ctr Groningen, Dept Radiol Nucl Med & Mol Imaging, Groningen, Netherlands
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2019年 / 185卷 / 04期
关键词：
FDG-PET; Hodgkin lymphoma; POSITRON-EMISSION-TOMOGRAPHY;
D O I：
10.1111/bjh.15602
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：758 / 760
页数：3
相关论文
共 50 条
  • [1] Controversies on the prognostic value of interim FDG-PET in advanced-stage Hodgkin lymphoma
    Adams, Hugo J. A.
    Kwee, Thomas C.
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2016, 97 (06) : 491 - 498
  • [2] Early chemotherapy intensification with BEACOPP in advanced-stage Hodgkin lymphoma patients with a interim-PET positive after two ABVD courses
    Gallamini, Andrea
    Patti, Caterina
    Viviani, Simonetta
    Rossi, Andrea
    Fiore, Francesca
    Di Raimondo, Francesco
    Cantonetti, Maria
    Stelitano, Caterina
    Feldman, Tatyana
    Gavarotti, Paolo
    Sorasio, Roberto
    Mule, Antonino
    Leone, Monica
    Rambaldi, Alessandro
    Biggi, Alberto
    Barrington, Sally
    Fallanca, Federico
    Ficola, Umberto
    Chauvie, Stephane
    Gianni, Alessandro Massimo
    BRITISH JOURNAL OF HAEMATOLOGY, 2011, 152 (05) : 551 - 560
  • [3] Does interim PET increase the value of ABVD in advanced-stage Hodgkin lymphoma?
    Gallamini, A.
    Kostakoglu, L.
    ANNALS OF ONCOLOGY, 2015, 26 (06) : 1045 - 1047
  • [4] Interim FDG-PET has no value in selecting patients who require treatment modification in both early- and advanced-stage Hodgkin lymphoma
    Adams, Hugo J. A.
    Kwee, Thomas C.
    BRITISH JOURNAL OF HAEMATOLOGY, 2018, 183 (01) : 129 - 131
  • [5] Outcome-based interpretation of early interim PET in advanced-stage Hodgkin lymphoma
    Kobe, Carsten
    Goergen, Helen
    Baues, Christian
    Kuhnert, Georg
    Voltin, Conrad-Amadeus
    Zijlstra, Josee
    Hoekstra, Otto
    Mettler, Jasmin
    Drzezga, Alexander
    Engert, Andreas
    Borchmann, Peter
    Dietlein, Markus
    BLOOD, 2018, 132 (21) : 2273 - 2279
  • [6] Will treatment intensification in early-stage Hodgkin lymphoma patients with a positive interim FDG-PET improve outcome?
    Adams, Hugo J. A.
    Kwee, Thomas C.
    PEDIATRIC HEMATOLOGY AND ONCOLOGY, 2016, 33 (01) : 1 - 4
  • [7] High-Risk, Advanced-Stage Hodgkin Lymphoma: The Impact of Combined Escalated BEACOPP and ABVD Treatment in Patients Who Rapidly Achieve Metabolic Complete Remission on Interim FDG-PET/CT Scan
    Kedmi, Meirav
    Apel, Arie
    Davidson, Tima
    Levi, Itai
    Dann, Eldad J.
    Polliack, Aaron
    Ben-Bassat, Isaac
    Nagler, Arnon
    Avigdor, Abraham
    ACTA HAEMATOLOGICA, 2016, 135 (03) : 156 - 161
  • [8] Does interim 18F-FDG-PET response-adapted therapy really benefit advanced-stage Hodgkin lymphoma patients?
    Adams, Hugo J. A.
    Kwee, Thomas C.
    NUCLEAR MEDICINE COMMUNICATIONS, 2016, 37 (12) : 1333 - 1334
  • [9] International Validation Study for Interim PET in ABVD-Treated, Advanced-Stage Hodgkin Lymphoma: Interpretation Criteria and Concordance Rate Among Reviewers
    Biggi, Alberto
    Gallamini, Andrea
    Chauvie, Stephane
    Hutchings, Martin
    Kostakoglu, Lale
    Gregianin, Michele
    Meignan, Michel
    Malkowski, Bogdan
    Hofman, Michael S.
    Barrington, Sally F.
    JOURNAL OF NUCLEAR MEDICINE, 2013, 54 (05) : 683 - 690
  • [10] Interim PET-guided ABVD or ABVD/escalated BEACOPP for newly diagnosed advanced-stage classic Hodgkin lymphoma (JCOG1305)
    Kusumoto, Shigeru
    Munakata, Wataru
    Machida, Ryunosuke
    Terauchi, Takashi
    Onaya, Hiroaki
    Oguchi, Masahiko
    Iida, Shinsuke
    Nosaka, Kisato
    Suzuki, Yasuhiro
    Harada, Yasuhiko
    Miyazaki, Kana
    Maruta, Masaki
    Fukuhara, Noriko
    Toubai, Tomomi
    Kubota, Nobuko
    Ohmachi, Ken
    Saito, Toko
    Rai, Shinya
    Mizuno, Ishikazu
    Fukuhara, Suguru
    Takeuchi, Mai
    Tateishi, Ukihide
    Maruyama, Dai
    Tsukasaki, Kunihiro
    Nagai, Hirokazu
    CANCER SCIENCE, 2024, 115 (10) : 3384 - 3393
12345